<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321748</url>
  </required_header>
  <id_info>
    <org_study_id>M522101-EU23</org_study_id>
    <nct_id>NCT02321748</nct_id>
  </id_info>
  <brief_title>Drug-Drug Interaction Study: ASP2151 and Montelukast</brief_title>
  <official_title>A Single-centre, Open-label, Randomised, Crossover, Drug-drug Interaction Study in Healthy Men to Investigate the Effect of a Single Dose of ASP2151 on the Pharmacokinetics of Montelukast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maruho Europe Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maruho Europe Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CYP2C8 is involved in the metabolism of many drugs. So, it is important to assess in vivo the
      inhibitory effect of ASP2151 on that enzyme to determine any possible drug interactions. The
      aim of this trial is to investigate the potential for interaction of ASP2151 with the CYP2C8
      probe substrate montelukast.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of Montelukast</measure>
    <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Peak Concentration (Tmax) of Montelukast</measure>
    <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of Montelukast</measure>
    <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-Life (t1/2) of Montelukast</measure>
    <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vd/f) of Montelukast</measure>
    <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Total Body Clearance (CL/f) of Montelukast</measure>
    <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious and Non-Serious Adverse Events</measure>
    <time_frame>Up to 32 days after the last dose</time_frame>
    <description>Refer to the result of adverse event.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Peak Plasma Concentration (Cmax) of Methyl Hydroxymontelukast</measure>
    <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time of Peak Concentration (Tmax) of Methyl Hydroxymontelukast</measure>
    <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Curve (AUC) of Methyl Hydroxymontelukast</measure>
    <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Half-Life (t1/2) of Methyl Hydroxymontelukast</measure>
    <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peak Plasma Concentration (Cmax) of ASP2151</measure>
    <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24h after post doses in first or second intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time of Peak Concentration (Tmax) of ASP2151</measure>
    <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24h after post doses in first or second intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area Under the Curve (AUC) of ASP2151</measure>
    <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24h after post doses in first or second intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Half-Life (t1/2) of ASP2151</measure>
    <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24h after post doses in first or second intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Apparent Volume of Distribution (Vd/f) of ASP2151</measure>
    <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24h after post doses in first or second intervention</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Apparent Total Body Clearance (CL/f) of ASP2151</measure>
    <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24h after post doses in first or second intervention</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP2151</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <arm_group_label>ASP2151</arm_group_label>
    <arm_group_label>Montelukast</arm_group_label>
    <other_name>SINGULAIR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP2151</intervention_name>
    <arm_group_label>ASP2151</arm_group_label>
    <arm_group_label>Montelukast</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A body mass index (Quetelet index) in the range 18.0-30.9.

          -  Sufficient intelligence to understand the nature of the trial and any hazards of
             participating in it. Ability to communicate satisfactorily with the investigator and
             to participate in, and comply with the requirements of, the entire trial.

          -  Willingness to give written consent to participate after reading the information and
             consent form, and after having the opportunity to discuss the trial with the
             investigator or his delegate.

          -  Willingness to give written consent to have data entered into The Overvolunteering
             Prevention System.

        Exclusion Criteria:

          -  Clinically relevant abnormal history, physical findings, ECG, or laboratory values at
             the pre-trial screening assessment that could interfere with the objectives of the
             trial or the safety of the volunteer.

          -  Any of the following liver function tests higher than 1.5 times the ULN at the
             screening visit: aspartate aminotransferase (AST), alanine aminotransferase (ALT),
             ALP, bilirubin, gamma glutamyl transpeptidase (gamma-GT).

          -  Platelet counts outside normal limits.

          -  Presence of acute or chronic illness or history of chronic illness sufficient to
             invalidate the volunteer's participation in the trial or make it unnecessarily
             hazardous.

          -  Clinically significant impaired endocrine, thyroid, hepatic, respiratory or renal
             function, diabetes mellitus, coronary heart disease, or history of any psychotic
             mental illness.

          -  History of bleeding diathesis.

          -  Surgery (eg stomach bypass) or medical condition that might affect absorption of
             medicines.

          -  Presence or history of severe adverse reaction to any drug, history of multiple drug
             allergies (multiple defined as &gt;3), or sensitivity to trial medication.

          -  Use, during the 28 days before the first dose of trial medication, of any prescription
             medicine, or any other medicine or herbal remedy (such as St John's wort) known to
             interfere with the CYP3A4, CYP2C19, CYP2C8 or CYP2C9 metabolic pathway (unless judged
             as not clinical significant by the investigator and sponsor). See Appendix 1: for
             common CYP3A4, CYP2C19, CYP2C8 and CYP2C9 interactors/substrates.

          -  Use, during the 7 days before the first dose of trial medication, of any over the
             counter medicine, with the exception of paracetamol (acetaminophen).

          -  Participation in another clinical trial of a new chemical entity or a prescription
             medicine within the previous 3 months.

          -  Presence or history of drug or alcohol abuse, or intake of more than 21 units of
             alcohol weekly or more than 10 cigarettes daily.

          -  Blood pressure and heart rate in seated position at the screening examination outside
             the ranges 90-140 mm Hg systolic, 40-90 mm Hg diastolic; heart rate 40_100 beats/min.
             However, if the investigator deems the result to be not clinically significant the
             subject may be included.

          -  Possibility that the volunteer will not cooperate with the requirements of the
             protocol.

          -  Evidence of drug abuse on urine testing.

          -  Positive test for hepatitis B, hepatitis C, HIV1 or HIV2.

          -  Loss of more than 400 mL blood during the 3 months before the trial, eg as a blood
             donor.

          -  Objection by General Practitioner (GP) to volunteer entering trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hammersmith Medicines Research Ltd</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>December 17, 2014</study_first_submitted>
  <study_first_submitted_qc>December 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <results_first_submitted>July 9, 2018</results_first_submitted>
  <results_first_submitted_qc>July 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2019</results_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HSV</keyword>
  <keyword>Herpes</keyword>
  <keyword>volunteers</keyword>
  <keyword>drug-drug interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at one investigative site in United Kingdom from 03-December 2014 to 01-April 2015</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Montelukast, Then Montelukast + ASP2151</title>
          <description>10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
Montelukast
ASP2151</description>
        </group>
        <group group_id="P2">
          <title>Montelukast + ASP2151, Then Montelukast</title>
          <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>First Intervention (4 Days)</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Wasout (2weeks)</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Second Intervention (4 Days)</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Montelukast, Then Montelukast + ASP2151</title>
          <description>10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
Montelukast
ASP2151</description>
        </group>
        <group group_id="B2">
          <title>Montelukast + ASP2151, Then Montelukast</title>
          <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.5" spread="7.7"/>
                    <measurement group_id="B2" value="33.2" spread="5.8"/>
                    <measurement group_id="B3" value="30.8" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Plasma Concentration (Cmax) of Montelukast</title>
        <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Montelukast</title>
            <description>10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
Montelukast
ASP2151</description>
          </group>
          <group group_id="O2">
            <title>ASP2151</title>
            <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax) of Montelukast</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="415.6" spread="24.9"/>
                    <measurement group_id="O2" value="505.9" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Peak Concentration (Tmax) of Montelukast</title>
        <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Montelukast</title>
            <description>10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
Montelukast
ASP2151</description>
          </group>
          <group group_id="O2">
            <title>ASP2151</title>
            <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Peak Concentration (Tmax) of Montelukast</title>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="3" lower_limit="1.50" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) of Montelukast</title>
        <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Montelukast</title>
            <description>10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
Montelukast
ASP2151</description>
          </group>
          <group group_id="O2">
            <title>ASP2151</title>
            <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of Montelukast</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2799.2" spread="29.7"/>
                    <measurement group_id="O2" value="3418.5" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-Life (t1/2) of Montelukast</title>
        <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Montelukast</title>
            <description>10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
Montelukast
ASP2151</description>
          </group>
          <group group_id="O2">
            <title>ASP2151</title>
            <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Half-Life (t1/2) of Montelukast</title>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" spread="27.8"/>
                    <measurement group_id="O2" value="5.37" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Volume of Distribution (Vd/f) of Montelukast</title>
        <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Montelukast</title>
            <description>10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
Montelukast
ASP2151</description>
          </group>
          <group group_id="O2">
            <title>ASP2151</title>
            <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vd/f) of Montelukast</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.72" spread="10.482"/>
                    <measurement group_id="O2" value="23.76" spread="7.854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apparent Total Body Clearance (CL/f) of Montelukast</title>
        <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Montelukast</title>
            <description>10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
Montelukast
ASP2151</description>
          </group>
          <group group_id="O2">
            <title>ASP2151</title>
            <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance (CL/f) of Montelukast</title>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" spread="1.079"/>
                    <measurement group_id="O2" value="3.04" spread="0.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious and Non-Serious Adverse Events</title>
        <description>Refer to the result of adverse event.</description>
        <time_frame>Up to 32 days after the last dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Montelukast Alone</title>
            <description>Participants received montelukast 10 mg alone in first or second intervation</description>
          </group>
          <group group_id="O2">
            <title>Montelukast With ASP2151</title>
            <description>Participants received montelukast 10 mg with ASP2151 400mg in first or second intervation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious and Non-Serious Adverse Events</title>
          <description>Refer to the result of adverse event.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Peak Plasma Concentration (Cmax) of Methyl Hydroxymontelukast</title>
        <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Montelukast</title>
            <description>10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
Montelukast
ASP2151</description>
          </group>
          <group group_id="O2">
            <title>ASP2151</title>
            <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax) of Methyl Hydroxymontelukast</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.18" spread="40.5"/>
                    <measurement group_id="O2" value="23.28" spread="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time of Peak Concentration (Tmax) of Methyl Hydroxymontelukast</title>
        <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Montelukast</title>
            <description>10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
Montelukast
ASP2151</description>
          </group>
          <group group_id="O2">
            <title>ASP2151</title>
            <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Peak Concentration (Tmax) of Methyl Hydroxymontelukast</title>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.51" lower_limit="3.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="5" lower_limit="2.50" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Curve (AUC) of Methyl Hydroxymontelukast</title>
        <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Montelukast</title>
            <description>10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
Montelukast
ASP2151</description>
          </group>
          <group group_id="O2">
            <title>ASP2151</title>
            <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of Methyl Hydroxymontelukast</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.19" spread="46.6"/>
                    <measurement group_id="O2" value="188.62" spread="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Half-Life (t1/2) of Methyl Hydroxymontelukast</title>
        <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.5, 1,1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 48 and 72h after post doses in first or second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Montelukast</title>
            <description>10mg montelukast alone followed by 10mg montelukast + 400mg ASP2151
Montelukast
ASP2151</description>
          </group>
          <group group_id="O2">
            <title>ASP2151</title>
            <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Half-Life (t1/2) of Methyl Hydroxymontelukast</title>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" spread="24.7"/>
                    <measurement group_id="O2" value="4.83" spread="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Peak Plasma Concentration (Cmax) of ASP2151</title>
        <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24h after post doses in first or second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASP2151</title>
            <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Plasma Concentration (Cmax) of ASP2151</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1679.7" spread="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time of Peak Concentration (Tmax) of ASP2151</title>
        <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24h after post doses in first or second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASP2151</title>
            <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Peak Concentration (Tmax) of ASP2151</title>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1.50" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Area Under the Curve (AUC) of ASP2151</title>
        <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24h after post doses in first or second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASP2151</title>
            <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of ASP2151</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20928.2" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Half-Life (t1/2) of ASP2151</title>
        <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24h after post doses in first or second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASP2151</title>
            <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Half-Life (t1/2) of ASP2151</title>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.406" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Apparent Volume of Distribution (Vd/f) of ASP2151</title>
        <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24h after post doses in first or second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASP2151</title>
            <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vd/f) of ASP2151</title>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246.9" spread="104.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Apparent Total Body Clearance (CL/f) of ASP2151</title>
        <time_frame>Blood samples were taken at pre-dose of Day 1 and 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 16 and 24h after post doses in first or second intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ASP2151</title>
            <description>10mg montelukast + 400mg ASP2151 followed by 10mg montelukast alone
Montelukast
ASP2151</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Total Body Clearance (CL/f) of ASP2151</title>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.95" spread="6.525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 32 days after the last dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Montelukast</title>
          <description>Participants received montelukast 10 mg alone in first or second intervention</description>
        </group>
        <group group_id="E2">
          <title>ASP2151</title>
          <description>Participants received montelukast 10 mg with ASP2151 400mg in first or second intervention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA/18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasopharynitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maruho Co.,Ltd. Kyoto R&amp;D Center</name_or_title>
      <organization>Clinical Development Dept.</organization>
      <phone>+81-75-325-3255</phone>
      <email>ctinfo@mii.maruho.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

